What is dalbavancin for?
Dalbavancin injection is used to treat acute bacterial skin and skin structure infections (ABSSSI). It belongs to the group of medicines known as antibiotics. Dalbavancin works by killing bacteria or preventing their growth.
What class of antibiotic is dalbavancin?
Dalbavancin is in a class of medications called lipoglycopeptide antibiotics. It works by killing bacteria.
When should I take dalbavancin?
There are also data suggesting that dalbavancin can be an effective treatment for bacteremia and infectious endocarditis (IE) [12,13,14,15,16,17]. First-line treatment for bacteremia and IE includes the use of parenteral antibiotics for 2–6 weeks, depending on pathogen and patient characteristics [18].
When was dalbavancin approved by the FDA?
Development Timeline for Dalvance
| Date | Article |
|---|---|
| May 23, 2014 | Approval FDA Approves Dalvance (dalbavancin) to Treat Skin Infections |
| Mar 31, 2014 | FDA Advisory Committee Unanimously Recommends Approval of Dalvance (dalbavancin) |
What are the side effects of dalbavancin?
The most common adverse reactions in patients treated with DALVANCE were nausea (4.7%), headache (3.8%), and diarrhea (3.4%). The median duration of adverse reactions was 3.0 days in patients treated with DALVANCE.
Does dalbavancin cover Pseudomonas?
Dalbavancin was intrinsically inactive against gram-negative bacteria. Like other glycopeptides, it possessed minimal activity against Haemophilus influenzae; Citrobacter, Acinetobacter, and Enterobacter spp.; Klebsiella pneumoniae; Escherichia coli; and Pseudomonas aeruginosa.
How do you administer dalbavancin?
DALVANCE is administered via intravenous infusion, using a total infusion time of 30 minutes to minimize the risk of infusion-related reactions. Rapid intravenous infusions of DALVANCE can cause reactions that resemble “Red-Man Syndrome,” including flushing of the upper body, urticaria, pruritus, and/or rash.
How is dalbavancin administered?
DALVANCE is administered via intravenous infusion, using a total infusion time of 30 minutes to minimize the risk of infusion-related reactions.
Does dalbavancin cover enterococcus?
Dalbavancin possesses in vitro activity against several gram-positive pathogens, including S. aureus, Streptococcus agalactiae, Streptococcus pyogenes, Streptococcus anginosus, Enterococcus faecium, and Enterococcus faecalis, although activity against enterococci has not been observed clinically [9, 15–18].
How long is dalbavancin infusion?
DALVANCE is administered as a 30-minute IV infusion.
How is dalbavancin metabolized?
Nearly 33% of dalbavancin is excreted in the urine unchanged, suggesting that non-renal methods of elimination play an important role in the metabolism of dalbavancin [28]. The extended half-life of dalbavancin is largely due to extensive, reversible binding to serum albumin, estimated to be roughly 95% [34].
What is the pharmacokinetics of dalbavancin?
Pharmacokinetics. Total protein binding of dalbavancin is concentration independent, reversible and estimated to be 93% ( 18 ). Animal studies regarding tissue distribution have demonstrated tissue concentrations reaching maximal levels within 24 h, with the highest concentrations in the liver and kidneys.
Does dalbavancin have a high cure rate for Gram-positive bone cancer?
The majority of patients in this trial had a gram-positive organism isolated from bone, consistent with previous literature. The dalbavancin group had high clinical cure rates at day 42 (97% in the CE, mITT, and micro-mITT populations), sustained through 1 year.
How well does Dalvance work in clinical trials?
The results of the clinical studies showed a majority of patients treated with DALVANCE stopped the spread of their skin infection and eliminated fever within 2-3 days. Were there any differences in how well the drug worked in clinical trials among sex, race and age? Subgroup analyses were conducted for sex, race and age.
Is dalbavancin an option for treatment of S aureus bacteremia?
Dalbavancin as an Option for Treatment of S. Aureus Bacteremia (DOTS): A Phase 2b, Multicenter, Randomized, Open-Label, Assessor-Blinded Superiority Study to Compare the Efficacy and Safety of Dalbavancin to Standard of Care Antibiotic Therapy for the Completion of Treatment of Patients With Complicated S. Aureus Bacteremia